SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Prednisone | Salbutamol / Albuterol |  Glutathione |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Mitochondrial / Metabolic Research |
| Pharmacology | Systemic glucocorticoid prodrug medicine | Short-acting beta-2 adrenergic agonist medicine | Endogenous antioxidant tripeptide / glutathione redox system; route-specific evidence |
| PrimeCore Class | Class AApproved in a bounded context | Class AApproved in a bounded context | Class AApproved in a bounded context |
| Evidence Grade | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence | Grade CEarly human evidence |
| Evidence boundary | Prednisone is classified here as Systemic glucocorticoid prodrug medicine. Extensive prescription evidence applies to disease-specific regimens and monitoring, not general recovery or performance use. FDA-authorised prescription products exist; WADA prohibits systemic glucocorticoids in competition by specified routes and requires current rule checking. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Salbutamol / Albuterol is classified here as Short-acting beta-2 adrenergic agonist medicine. Strong clinical evidence applies to authorised inhaled products and respiratory indications, not catalogue tablets for weight loss or performance. FDA-authorised respiratory products exist; WADA permits only specified inhaled salbutamol conditions and thresholds, while other routes/use are prohibited. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Glutathione is an endogenous antioxidant tripeptide. Reduced GSH, oxidised GSSG, oral and topical formulations, injectable products and GlyNAC precursors must be distinguished. Small human studies show mixed skin and biomarker results: the 2017 oral trial did not show significant overall melanin-index or UV-spot differences versus placebo. Biomarker changes do not establish disease prevention or longer life, and oral/topical evidence does not establish injection safety. Class A refers only to verified Tathion oral medicine in Japan, not skin-whitening approval; Grade C describes the limited human evidence reviewed here. FDA's 27 August 2026 alert reported at least 30 patients with adverse events following IV glutathione involving dietary-supplement-grade material and endotoxin concerns. Exact supplier-product status remains unverified. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
|
| Insufficient data in the current dataset |
| Sources |
| ||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions